• Explore /
  • Poster
  • / Phase I study combining pembrolizumab and aromatase inhibitor in patients with metastatic hormone receptor–positive breast cancer.

Phase I study combining pembrolizumab and aromatase inhibitor in patients with metastatic hormone receptor–positive breast cancer.

Abstract Poster

Authors

null

Xuan Ge

City of Hope, Duarte, CA

Xuan Ge , Susan Elaine Yost , Jin Sun Lee , Paul Henry Frankel , Christopher Ruel , Yujie Cui , Mireya Murga , Aileen Tang , Norma Martinez , Samuel Chung , Christina Haeyoung Yeon , Daphne B. Stewart , Daneng Li , Swapnil Padmakar Rajurkar , George Somlo , Joanne E. Mortimer , James Ross Waisman , Yuan Yuan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT 02648477

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 1053)

DOI

10.1200/JCO.2022.40.16_suppl.1053

Abstract #

1053

Poster Bd #

431

Abstract Disclosures

Similar Posters

First Author: Sara M. Tolaney

First Author: Igor Tsaur

First Author: Ana Christina Garrido-Castro

First Author: Neelima Vidula